Image: Nathan Rimoux / Unsplash. Illustrative photography; it does not depict the trial or product.
Short human trials show increases in blood NAD-related measures. Some report changes in specific functional outcomes, but they have not established that NMN extends human lifespan or prevents age-related disease.
Why everyone is watching NAD+
NAD+ is involved in cellular energy metabolism and other processes. NMN is a precursor in pathways that make NAD+. Ageing biology gives the topic a compelling rationale; it does not turn a higher blood measurement into proof of slower human ageing.
Signals from human studies
A randomised trial in postmenopausal women with prediabetes found improved muscle insulin sensitivity after NMN, while several other metabolic outcomes did not improve. A separate trial in older adults reported increases in blood NAD+ and some measures of walking speed and sleep quality. These are specific groups and endpoints, and the findings need independent replication.
The wider view
A systematic review of randomised trials found insufficient evidence for meaningful improvements in common glucose and lipid measures. Short trials can help assess tolerability under study conditions, but they cannot settle long-term safety or tell us whether a person will live longer or feel better years later.
A better question for a product label
Ask which form and dose were studied, in whom, for how long and against what outcome. A dramatic increase in a biomarker is the start of a research question, not the end of it. We will update this piece as longer and larger trials arrive.
Follow the evidence
- Yoshino et al., muscle insulin sensitivity trial ↗
- Morifuji et al., older-adult trial ↗
- Zhang et al., metabolic-outcome systematic review ↗
Research changes. This article is educational and is not a diagnosis, treatment plan or a recommendation to start a supplement. Last reviewed 27 September 2026.